Trial Profile

A Phase 1, Open-label, Multicenter Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 19 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BMS 986360 (Primary) ; Capecitabine; Docetaxel; Nivolumab
Indications Adenocarcinoma; Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Pancreatic cancer; Renal cell carcinoma; Sarcoma; Squamous cell cancer; Triple negative breast cancer
Focus Adverse reactions
Sponsors Bristol-Myers Squibb

Most Recent Events

13 Jun 2025 Status changed from active, no longer recruiting to completed.
08 May 2025 Status changed from recruiting to active, no longer recruiting.
09 Jan 2023 Planned End Date changed from 9 Aug 2027 to 30 Jul 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com